Back to Products
Factor VIIa is indicated for:
- Treatment of bleeding episodes in hemophilia A or B patients with inhibitors to Factor VIII or Factor IX and in patients with acquired hemophilia.
- Prevention of bleeding in surgical interventions or invasive procedures in hemophilia A or B patients with inhibitors to Factor VIII or Factor IX and in patients with acquired hemophilia.
- Treatment of bleeding episodes in patients with congenital FVII deficiency.
- Prevention of bleeding in surgical interventions or invasive procedures in patients with congenital FVII deficiency.
The estimated market for Factor VIIa is $1.3 billion.